Clinical value orientation makes doctors a part of the pharmaceutical industry chain

In recent years, China's drug R&D and clinical trials have developed rapidly.

At the China International Trade Fair on Clinical Oncology and Anti-tumor Drug Innovation and Research Forum held recently, the participating experts agreed that clinical value-oriented anti-tumor drug research and development is an important development direction, and first-line doctors or professors should Actively become a link in the pharmaceutical industry chain

"The gap between China and the international advanced level lies in the discovery of targets.

Huang Xiaojun added that China has now begun to pay attention to this aspect.

Wang Jie, a professor at the Cancer Hospital of the Chinese Academy of Medical Sciences, is very much looking forward to allowing and encouraging doctors or professors to "cross-border" development

"Foreign countries have already taken this path.

Yang Dajun, Chairman and CEO of Yasheng Pharmaceuticals, was a professor at an American university and founded the company during his teaching

"The United States encourages professors to start companies.

At present, some cities in southern China, such as Shanghai and Suzhou, are already far ahead, and some pilot companies have found good solutions

"I believe it will become a trend in the future, and the orientation of clinical value is also the country's policy orientation

Shen Lin believes that the era of precision treatment has arrived, and clinically more precise drugs are needed

Wang Jie took lung cancer as an example and said that compared with other cancers, lung cancer has many targets and many drugs, but how to accurately apply and refine the stratification is a question that lung cancer researchers around the world are thinking about

"I hope that scientists, pharmaceutical companies, and doctors will participate in this process to turn clinical problems into scientific problems, so that targets can be found in different groups of people and at different stages of treatment in the fastest time

In terms of international cooperation in new drug research and development, in the past five years, from studying and participating in China, more and more Chinese scholars have become global PIs (investigators in charge of clinical drug research institutions), but the gap is still large

"Chinese patients have their own characteristics and needs.

"The development of new drugs based on clinical value and clinical issues will enable Chinese doctors to lead these studies more and give us a stronger voice in the field of global cancer research,

Experts at the meeting believe that doctors often have a deep understanding of diseases and will publish some papers.
This is the source of the "target", but most doctors or professors do not have a strong business sense, which is not conducive to the development of innovative drugs.

.

"Doctors must take the initiative to become a link in the pharmaceutical production chain
.
" Huang Xiaojun added, "Only when the level of Chinese doctors is up, China can become a real pharmaceutical power
.
"

There are many cases of many diseases in China, such as nasopharyngeal cancer.
In the future, China will have a greater say in the development of new drugs based on the characteristics of Chinese cases and the needs of patients
.

"Whether it is a multinational company or a Chinese company, they must change their
minds now .
" Shen Lin said, "China has contributed so many cases and has such a large market.
Exploring these aspects may be the source of future innovation
.
I believe in the next few years.
People from all walks of life working together will definitely improve the quality of life of Chinese cancer patients and bring revolutionary progress to cancer treatment
.
"